

Hala T Borno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4482323/publications.pdf>

Version: 2024-02-01

39
papers

542
citations

759233

12
h-index

713466

21
g-index

39
all docs

39
docs citations

39
times ranked

875
citing authors

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	4
2	Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. <i>JCO Oncology Practice</i> , 2022, 18, e915-e924.	2.9	7
3	The Problem of Hispanic/Latinx Under-Representation in Cancer Clinical Trials. <i>JCO Oncology Practice</i> , 2022, 18, 380-384.	2.9	14
4	Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100182.	2.1	0
5	Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center. <i>Journal of Nuclear Medicine</i> , 2021, 62, 695-699.	5.0	21
6	Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. <i>Cancer Medicine</i> , 2021, 10, 62-69.	2.8	0
7	Disparities in precision medicine—Examining germline genetic counseling and testing patterns among men with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 233.e9-233.e14.	1.6	11
8	Oncology patients' perceptions of and experiences with COVID-19. <i>Supportive Care in Cancer</i> , 2021, 29, 1941-1950.	2.2	27
9	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. <i>Cancer Reports</i> , 2021, 4, e1355.	1.4	2
10	Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.	4.1	15
11	Policy and Health: Leveraging a Social Determinants of Health Framework to Alleviate the Impact of the COVID-19 Pandemic on Patients With Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 121-124.	2.9	8
12	Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 47-62.	0.4	2
13	Prostate cancer patients' self-reported participation in research: an examination of racial/ethnic disparities. <i>Cancer Causes and Control</i> , 2021, 32, 1161-1172.	1.8	4
14	Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 494.e7-494.e14.	1.6	4
15	Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. <i>Journal of Cancer Policy</i> , 2021, 30, 100305.	1.4	13
16	The Distance Between Us: the COVID-19 Pandemic's Effects on Burnout Among Resident Physicians. <i>Medical Science Educator</i> , 2021, 31, 2065-2069.	1.5	7
17	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100480.	2.9	1
18	Tailoring survivorship to diverse populations with genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 118-120.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Ethnic disparities among men with prostate cancer undergoing germline testing. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 80.e1-80.e7.	1.6	32
20	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
21	COVID-19 disparities: An urgent call for race reporting and representation in clinical research. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100630.	1.1	40
22	Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 793.e1-793.e11.	1.6	7
23	Stress and Symptom Burden in Oncology Patients During the COVID-19 Pandemic. <i>Journal of Pain and Symptom Management</i> , 2020, 60, e25-e34.	1.2	89
24	Determining the impact of Medicaid expansion on cancer burden. <i>Cancer</i> , 2020, 126, 4114-4117.	4.1	2
25	The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer. <i>Journal of Racial and Ethnic Health Disparities</i> , 2020, 7, 996-1002.	3.2	11
26	Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?. <i>Contemporary Clinical Trials</i> , 2020, 92, 105997.	1.8	8
27	Racial disparities and online health information: YouTube and prostate cancer clinical trials. <i>BJU International</i> , 2020, 126, 11-13.	2.5	10
28	Food insecurity screening: A missing piece in cancer management. <i>Cancer</i> , 2019, 125, 3494-3501.	4.1	31
29	All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 302-308.	3.8	26
30	A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. <i>Pilot and Feasibility Studies</i> , 2019, 5, 123.	1.2	7
31	How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100476.	1.1	10
32	Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. <i>Cancer</i> , 2019, 125, 453-462.	4.1	13
33	At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials. <i>Oncologist</i> , 2018, 23, 1242-1249.	3.7	70
34	A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 60-67.	1.1	10
35	An unusual manifestation of diabetic ketoacidosis and acute colonic pseudo-obstruction. <i>JRSM Open</i> , 2017, 8, 205427041769863.	0.5	2
36	Improving documentation of surrogate decision makers in medical oncology clinic.. <i>Journal of Clinical Oncology</i> , 2017, 35, 63-63.	1.6	0

#	ARTICLE	IF	CITATIONS
37	The problem of representativeness of clinical trial participants: understanding the role of hidden costs. <i>Journal of Health Services Research and Policy</i> , 2016, 21, 145-146.	1.7	9
38	Broad inclusion leads to maximal value â€“ examining travel costs associated with clinical trial participation. <i>International Journal of Cancer Care and Delivery</i> , 0, , .	0.0	1
39	Implementation of a medical oncology fellow-initiated financial toxicity screening program in outpatient medical oncology clinics. <i>International Journal of Cancer Care and Delivery</i> , 0, , .	0.0	0